Arbutus
Warminster, United Kingdom · Biopharma, Biotechnology, Healthcare
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing
Key facts
- Headquarters
- Warminster, United Kingdom
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (AVBP)
- Website
- arbutusbio.com
- Company page
Recent activity at Arbutus
- : SEC 8-K (8.01): On May 11, 2026, ArriVent BioPharma, Inc. filed a prospectus supplement related to its existing 'at the market offering' program. The prospectus allows the Company to sell shares of its common stock up to an aggregate offering price of $250,000,000 through Jefferies LLC as the sales agent. This action is part of an ongoing strategy to raise capital, utilizing the Open Market Sale Agreement dated February 3, 2025, which was filed under an automatic shelf registration statement effective since that date. This move reflects the company's intent to enhance liquidity and support potential growth initiatives.
- : SEC 8-K (7.01): On March 17, 2026, ArriVent BioPharma, Inc. issued a press release announcing its participation at the 2026 AACR Annual Meeting, where the company plans to present two preclinical posters. These will focus on the EGFR inhibitor firmonertinib and the novel dual-target MUC16/NaPi2b tetravalent ADC ARR-002. This disclosure provides insight into the Company's ongoing research efforts and collaboration in the field of oncology, highlighting their potential advancements in cancer treatment. The presentation at a notable conference like the AACR underscores the strategic importance of these compounds to the company’s future prospects.
- : Arbutus Biopharma urged to seek partnership for hepatitis B cure development
- : Arbutus Announces CEO, William Collier, to Retire December 31, 2023
- : Arbutus Biopharma appoints Karen Sims as chief medical officer (NASDAQ:ABUS) | Seeking Alpha
- : ArriVent Biopharma, Inc.
- : Arbutus Biopharma Corp
- : ArriVent Biopharma, Inc.
Arbutus funding history
| Date | Round | Amount |
|---|---|---|
| Feb 2022 | Venture | $150.0M |
| Dec 2021 | Venture | $15.0M |
| Jun 2021 | Venture | $81.0M |
Leadership
- William Collier, Executive Officer, Director
- Frank Torti, Director
- Daniel Burgess, Director
- Richard Henriques, Director
- Keith Manchester, Director
- Eric Venker, Director
- James Meyers, Director
- Andrew Cheng, Director
- Tram Tran, Director
- Zhengbin Yao, Executive Officer, Director
- Michael McElhaugh, Chief Executive Officer
- Karen Sims, Chief Medical Officer
Verified email and direct lines for Arbutus’s decision-makers are on Fundz. See plans
Employee benefit plans
Arbutus files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Arbutus in the news
- Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire (May 13, 2026)
- Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire (Aug 12, 2026)
- Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer - GlobeNewswire (Sep 30, 2026)
- Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - GlobeNewswire (Jul 16, 2026)
- Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - GlobeNewswire (Apr 15, 2026)
- Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewswire (Mar 03, 2026)
Companies similar to Arbutus
- AbbVie Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Corvus Pharmaceuticals, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- ISOThrive · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Mereo Biopharma Group plc · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- vTv Therapeutics Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Arbutus: questions and answers
What does Arbutus do?
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing
Where is Arbutus headquartered?
Arbutus is headquartered in Warminster, United Kingdom.
Has Arbutus raised funding?
Yes. Fundz has recorded 3 funding events for Arbutus. The most recent, $150.0M, was in Feb 2022.
Who leads Arbutus?
Michael McElhaugh is a Chief Executive Officer at Arbutus.
What is the latest news on Arbutus?
On May 11, 2026, SEC 8-K (8.01): On May 11, 2026, ArriVent BioPharma, Inc. filed a prospectus supplement related to its existing 'at the market offering' program. The prospectus allows the Company to sell shares of its common stock up to an aggregate offering price of $250,000,000 through Jefferies LLC as the sales
Is Arbutus a public company?
Yes. Arbutus is publicly traded under the ticker AVBP.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy